Which 3 NZX healthcare stocks can be considered in 2022?

Be the First to Comment Read

Which 3 NZX healthcare stocks can be considered in 2022?

healthcare stocks
Image source: Ratanapon Srisuneton, Shutterstock.com

Highlights

  • NZ offers a high-quality healthcare system that protects the health of its people.
  • Summerset Group Holdings posts strong 4Q21 metrics.
  • Cannasouth takes significant research initiatives to develop cost-effective extracts for the treatment.

New Zealand boasts having one of the finest healthcare industries across the world.

With a rising population marked by a huge proportion of the elderly and increased health expectations, NZ healthcare companies are consistently working offering high standards of care and attention both to their patients as well as customers.

Having said that, let us get acquainted with the three NZ healthcare stocks worth looking at this year.

NZ healthcare stocks – SUM, CBD, TRU

Source: © 2022 Kalkine Media® data source- Refinitiv

Summerset Group Holdings Limited (NZX:SUM)

Summerset Group Holdings Limited released its 4Q21 metrics a few days ago. It stated that despite Waikato and Auckland being under lockdowns for the majority of the quarter, the Company’s Q4 sales remained strong with 234 being the total sales for the said quarter.

Must Read: How are 3 NZX retirement villages faring amid Omicron outbreak?

Further, SUM revealed that cumulative sales for 2021 were up by 25% on FY20 and it maintains a positive outlook for 1Q22, with 58% of new presold deliveries.

Also, this year would witness the commencement of construction at SUM’s four new sites.

At the closing bell on 25 January, Summerset Group Holdings was down by 0.08% at NZ$12.140.

Cannasouth Limited (NZX:CBD)

Cannasouth Limited has recently announced funding support from Callaghan Innovation for taking significant research initiatives.

Its research activities include working on affordable extracts through various new-age technologies and developing cost-effective treatments to cure specific conditions.

Also Read: Look at these 5 NZX-listed penny stocks for 2022

Also, CBD would undertake a detailed study of clinical trials so as to support successful outcomes.

At the closing bell on 25 January, Cannasouth declined by 2.74% at NZ$0.355.

TruScreen Group Limited (NZX:TRU)

TruScreen Group Limited has revealed of making significant progress across its major markets across the globe.

Related Read: TruScreen (NZX:TRU) reports strong revenue growth of 25%

One of the leading hospitals of Vietnam has replaced its traditional cervical cancer screening technology with TRU’s advanced cervical cancer detection technology, thus paving the way for a significant rise in TruScreen’s usage across the country.

Further, its Russian distributor is continuously working on raising awareness regarding TRU’s technology throughout the Russian Federation.

Moreover, the Company’s Mexican distributor has teamed up with a regional medical device financing company, thereby giving TRU a strong clientele of 3,000 private and public hospitals.

At the closing bell on 25 January, TruScreen Group’s shares climbed by 1.22% at NZ$0.083.

Bottom Line

The Healthcare sector of the country has remained resilient amid the pandemic and is continuously working on safeguarding the health of its people.

Disclaimer

Speak your Mind

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK